Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Summary

Phase II trial to study the effectiveness of combining oblimersen with imatinib mesylate in treating patients who have chronic myelogenous leukemia that has not responded to previous treatment with imatinib mesylate. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Oblimersen may help imatinib mesylate kill more cancer cells by making cancer cells more sensitive to the drug.

Timeline

Start

2002-11

Primary completion

2005-11

Completion

—

Drugs

Indications